Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-cell memory after primary or booster MenC vaccination in adults
NL-OMON27223Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- May 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of meningococcal serogroup C conjugate vaccine and meningococcal serogroup C polysaccharide vaccine in meningococcal disease (3 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Characterization of memory B-cell response after MenC vaccination. Started May 2007; status: active, not recruiting.
02
Drugs
meningococcal serogroup C conjugate vaccinemeningococcal serogroup C polysaccharide vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NL-OMON27223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27223.